指南与共识泌尿生殖技术与安全PETCT

EAU-EANM-ESTRO-ESUR-SIOG前列腺癌指南第二部分-2020更新:复发性和转移性前列腺癌的治疗

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
指南 / 共识 · Eur Urol · 2020-10-07

该指南由EAU、EANM、ESTRO、ESUR和SIOG联合制定,基于2016-2019年文献的系统综述更新,并添加了证据水平和/或推荐等级。指南总结了PSMA PET/CT在生化复发中的作用、根治性前列腺切除术后早期挽救性放疗与辅助放疗的等效性及联合雄激素剥夺的适用人群,以及转移性激素敏感型、非转移性CRPC和转移性CRPC的新治疗选择和低体积转移性激素敏感型前列腺癌局部放疗的作用,并纳入生活质量结局信息。

要点

  • PSMA PET/CT在局部治疗后生化复发患者中的作用日益重要。
  • 根治性前列腺切除术后早期挽救性放疗似乎与辅助放疗同样有效,部分患者应联合雄激素剥夺治疗。
  • 转移性激素敏感型、非转移性CRPC和转移性CRPC已有新治疗,低体积转移性激素敏感型前列腺癌可考虑局部放疗。

核心结论

  • 晚期、转移性前列腺癌和CRPC领域的知识正在快速变化,2020年EAU-EANM-ESTRO-ESUR-SIOG指南总结了最新发现和临床实践建议。

研究设计与样本

  • 该指南由EAU、EANM、ESTRO、ESUR和SIOG联合制定,工作组对2016-2019年新数据进行了文献综述,基于系统文献综述更新指南并添加证据水平和/或推荐等级。

诊断标准与关键数值

  • PSMA PET/CT在局部治疗后生化复发患者中作用日益重要;早期挽救性放疗在根治性前列腺切除术后似乎与辅助放疗同样有效,部分患者应联合雄激素剥夺治疗。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC).

EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2016-2019). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature.

EVIDENCE SYNTHESIS: Prostate-specific membrane antigen positron emission tomography computed tomography scanning has developed an increasingly important role in men with biochemical recurrence after local therapy. Early salvage radiotherapy after radical prostatectomy appears as effective as adjuvant radiotherapy and, in a subset of patients, should be combined with androgen deprivation. New treatments have become available for men with metastatic hormone-sensitive prostate cancer (PCa), nonmetastatic CRPC, and metastatic CRPC, along with a role for local radiotherapy in men with low-volume metastatic hormone-sensitive PCa. Also included is information on quality of life outcomes in men with PCa.

CONCLUSIONS: The knowledge in the field of advanced and metastatic PCa and CRPC is changing rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are first endorsed by the EANM and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/).

PATIENT SUMMARY: This article summarises the guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are evidence based and guide the clinician in the discussion with the patient on the treatment decisions to be taken. These guidelines are updated every year; this summary spans the 2017-2020 period of new evidence.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2020. PMID: 33039206. doi:10.1016/j.eururo.2020.09.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。